Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2017
Pharmacy Choice - News - Pharmaceutical Development - October 20, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/20/17 - 2017 DrugDev Summit, Co-Chaired by Novartis and CSL Behring, to Convene 100+ Clinical Leaders to Improve the Clinical Trial Experience for Patients, Sites and Study Teams [Sport360]
-The worlds most progressive pharmaceutical companies, CROs and sites will continue to advance beyond the clinical trial status quo at the 2017 DrugDev Summit in Philadelphia, November 7-8. Co-chaired by Novartis and CSL Behring, DrugDevs annual Summit is widely regarded by customers as the premier open forum for sharing clinical trial best practic
10/20/17 - Abbott Reports Third Quarter 2017 Results
Excluding specified items, adjusted diluted EPS from continuing operations was $0.66 in the third quarter, at the high end of the previous guidance range of $0.64 to $0.66. In September, Abbott received U.S. FDA approval for its FreeStyle Libre glucose monitoring system as a replacement1 for finger stick blood glucose monitoring. During the quarter
10/20/17 - AcelRx's DSUVIA? Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY 2017
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical, today announced its clinical data presentation on the safety and efficacy of DSUVIA?, 30 mcg classified by age group across four clinical trials at the American Society of Anesthesiologists' ANESTHESIOLOGY 2017 Annual Meeting. The information presented during the session was authored
10/20/17 - Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hATTR amyloidosis, will be presented at the 1 st European ATTR Amyloidosis Meeting for Patients an
10/20/17 - AstraZeneca - US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck& Co., Inc., today announced that the US Food and Drug Administration has accepted and granted Priority Review for a supplemental New Drug Application for the use of Lynparza tablets in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuva
10/20/17 - Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS) [Syrian Arab News Agency]
Atara Biotherapeutics, Inc., a leading "off-the-shelf", or allogeneic, T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases, announced today that the Company initiated a multinational, multicenter Phase 1 clinical study to evaluate allogeneic ATA188 in patients with progressive or...
10/20/17 - BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy [T-break Tech (Middle East)]
BioLife Solutions, Inc., the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that its customer Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, has received US FDA approval for Yescarta, the first CAR T-cell therapy for.
10/20/17 - Bristol-Myers Squibb to Present New Data Advancing Research Across Serious Liver Diseases at The Liver Meeting 2017
Bristol-Myers Squibb Company today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis and hepatocellular carcinoma, will be presented at The Liver Meeting 2017 in Washington, DC, October 20 24, 2017.. The data being presented at The Liver Meeting demonstrate our commitment to advancing the scie
10/20/17 - Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda [Sudan Tribune]
Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the first patient has been treated in the Phase 1 cohort of INCB01158 in combination with Keytruda, an.
10/20/17 - Cerus Announces First Biologics License Application Approval for U.S. Blood Center Customer
By a News Reporter-Staff News Editor at Genomics& Genetics Weekly Cerus Corporation announced that Rhode Island Blood Center received approval by the U.S. Food and Drug Administration on their Biologics License Application requesting allowance for interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System
10/20/17 - ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL [Sudan Tribune]
-ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has dosed its first patient in the IND opening, Phase 1 study of tenofovir exalidex in renally-impaired patients. The study to be conducted in the U.S. will assess the safety and...
10/20/17 - Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Reports Positive Results From Anabasum Dermatomyositis Trial
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has announced that it has observed positive results from its Phase 2 clinical study of its drug anabasum that is aimed at treating dermatomyositis. The biopharma was pleased to announce the positive results of the anabasum clinical trial results. Corbus has been developing the drug for treating derm
10/20/17 - CStone Pharmaceuticals Announces Dosing the First Patient of CS1001: China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody
CStone Pharmaceuticals Co., Ltd. announced today that the first human clinical trial of CS1001, China's first fully human and full-length anti-PD-L1 monoclonal antibody, had successfully dosed the first patient in Beijing Cancer Hospital. Frank Jiang, CEO of CStone Pharmaceuticals. " After the successful enrollment of the first patient, CStone...
10/20/17 - Dalton Pharma Services Officially Recertified as a Great Place to Work [Sport360]
Daltons success is the result of how we value our employees and encourage work-life balance, explained Peter Pekos, President and CEO. We are FDA registered and Health Canada approved and bring over 30 years of experience to every project. We are experts in Custom Synthesis, cGMP API Manufacturing, Formulation Development, API Process Development,
10/20/17 - Dana-Farber, Brigham & Women's Researchers Laud FDA Approval of CAR T-Cell Therapy for Non-Hodgkin Lymphoma
Brigham and Women's Hospital issued the following news release:. Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor T-cell therapy for adult cancers was approved by the Food and Drug Administration today. "Treating patients with CAR T-cells has been one
10/20/17 - Dana-Farber, Brigham and Women's Researchers Laud FDA Approval of CAR T-Cell Therapy for Non-Hodgkin Lymphoma
The Dana-Farber Cancer Institute issued the following news release:. Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor T-cell therapy for adult cancers was approved by the Food and Drug Administration today. "Treating patients with CAR T-cells has been
10/20/17 - Developing Treatments for Blindness in Children: The Role of the Paediatric Medicines Regulation (PMR)
The European Federation of Pharmaceutical Industries and Associations issued the following news release:. With over 7000 medicines in development, new treatments will continue to change patients' lives; slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicines is a long, complex
10/20/17 - DGAP-Adhoc: BB BIOTECH AG: Product approvals and solid company results lead the biotech sector higher (english)
BB BIOTECH AG: Product approvals and solid company results lead the biotech sector higher ^ DGAP-Ad-hoc: BB BIOTECH AG/ Key word: 9- month figures BB BIOTECH AG: Product approvals and solid company results lead the biotech sector higher 20- Oct-2017/ 07:00 CET/ CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP- a
10/20/17 - Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate Tablets in the U.S. Market
By a News Reporter-Staff News Editor at Drug Week Dr. Reddy's Laboratories Ltd. announced that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela Tablets, approved by the U.S. Food and Drug Administration. "We are very pleased to bring Sevelamer Carbonate Tablets to market at this time," s
10/20/17 - Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma
Emerald Health Pharmaceuticals Inc., which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. "Orphan designation represents an important regulatory milestone for our compa
10/20/17 - Enanta Pharmaceuticals to Present New Preclinical Data on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting 2017
Enanta Pharmaceuticals, Inc., a chemistry-driven biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced new data presentations on EDP-305, Enanta s lead Farnesoid X receptor agonist being developed for non-alcoholic steatohepatitis and primary biliary cholangitis,.
10/20/17 - FDA approves new cancer treatment with Israeli pedigree [Globes, Tel Aviv, Israel]
Oct. 20 Kite Pharma, bought by Gilead Sciences for $12 billion in August this year, has announced that the US Food and Drug Administration has granted regular approval to its cancer treatment Yescarta. The product was approve on a fast-track process. Because of the combination of this process and the innovativeness of the product there were fears
10/20/17 - FDA Approves Radical New Gene-Altering Cancer Treatment [Tehran Times (Iran)]
On 18 October the Food and Drug Administration approved the second gene-altering cancer treatment for patients with diffuse large B-cell lymphoma, the most common aggressive type of non-Hodgkin lymphoma, a blood cancer. The new therapy, Yescarta, is now approved only for adults who have had two or more failed chemotherapy regimens. Today is an impo
10/20/17 - FDA approves Yescarta to treat adults with B-cell lymphoma [Sudan Tribune]
The U.S. Food and Drug Administration has approved Yescarta, a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor T cell therapy, is the second gene therapy approved by the FDA a
10/20/17 - FDA-Approved Clinical Trial Tests Stem Cells to Heal Wounds [Sport360]
-Sanford Health is launching its second adipose-derived stem cell clinical trial this one to focus on non-healing leg wounds. We have a mission here at Sanford to use research and clinical trials to make a real difference in peoples lives, said David Pearce, Ph.D., executive vice president of innovation and research at Sanford Health. Sanford Healt
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415